Dry AMD, the most typical form of the disease, represents approximately 85 to 90 % of all AMD cases in the united states. Currently, there is absolutely no FDA approved treatment for dry AMD.. Age-related macular degeneration patient receives investigational eye drops An 88-year-old man at The Methodist Medical center in Houston is one of two patients in the world today to receive an investigational attention drop that may restore sight for those suffering from neovascular age-related macular degeneration, a major reason behind central visual reduction and among the leading factors behind blindness in people over 60 in the United States. Currently, the typical treatment requires multiple injections into the diseased attention.ZANAFLEX CAPSULES and ZANAFLEX tablets shipments – Total ZANAFLEX CAPSULES and ZANAFLEX tablets shipments for the one fourth ended December 31, 2010 were $15.8 million, in comparison to total shipments of $18.4 million for the same quarter in 2009 2009. For the entire year ended December 31, 2010, total ZANAFLEX CAPSULES and ZANAFLEX tablet shipments had been $57.3 million, in comparison to total shipments of $66.7 million in 2009 2009. December 31 Research and development expenses for the one fourth ended, 2010 had been $8.0 million, including $1.6 million of share-based compensation, in comparison to $10.6 million including $1.1 million of share-based compensation for the same quarter in ’09 2009.